Skip to main content
Premium Trial:

Request an Annual Quote

Indi Molecular Raises Additional $300K in Seed Funding

NEW YORK (GenomeWeb News) – Indi Molecular said today that it has raised $300,000 from a new investor, Asset Management Ventures.

With this investment, Indi Molecular has expanded the amount raised in its seed round to a total of $1.8 million, which it will use to further development of its protein catalyzed capture reagents, a synthetic affinity agent technology that the company hopes to market as an alternative to traditional antibodies.

According to the firm, PCCs have several potential advantages over monoclonal antibodies including better specificity and the ability to target regions of proteins not accessible to monoclonals.

Indi Molecular is a spinoff of proteomics firm Integrated Diagnostics. It launched as a separate entity in September with $1.5 million in seed funding from InterWest Partners and company co-founders including Albert Luderer – CEO of both Indi and Indi Molecular – California Institute of Technology researcher James Heath, Lee Hood, and University of California, Los Angeles, professor and inventor of PET imaging, Michael Phelps.

Indi initially aimed to spinoff the PCC business in 2012, but delayed these plans due to difficulties in lining up the needed financing.

The company also announced the recent publication of three peer-reviewed papers detailing use of the PCC reagents for purposes including detection of highly-specific protein regions, diagnosis of HIV, and detection of anthrax.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.